1. Introduction {#s0005}
===============

Adeno-associated viruses (AAV) have never been associated with any human disease and, thus have been most successfully used as a delivery vector for gene therapies. The first licenced gene therapy product for human use ([@bib6]) is based on AAV and AAV products have been continuously improved for clinical applications, e.g. for haemophilia B ([@bib36]), heart disease ([@bib25]) and congenital blindness ([@bib5]). Although many advances in AAV vector design have been made, the production of high titre AAV is still a significant challenge as in the case of the first marketed product Glybera, which is required to be administered to patients as a dose of 3 × 10^12^ vg /kg via 40 or 60 multiple injections ([@bib6]).

The limitation in high titre AAV production may be due to the AAV dependence on helper viruses and insufficient understanding of factors, viral or cellular, that contribute to AAV replication. It has been well documented that AAV *rep* gene expression and AAV DNA replication depended on AAV interaction with a helper virus, e.g. adenovirus, herpes-virus or papillomavirus ([@bib8], [@bib34], [@bib40]); however, a number of studies have otherwise suggested that none of the helper virus genes was directly involved in AAV replication and that the helper function was to induce cellular factors that were missing or inactivated in a normal cell cycle, emphasising the importance of cellular factors in the AAV life cycle ([@bib34], [@bib38]). For example, helper viruses have been demonstrated to induce entry of the host cell into S-phase and lead to changes of cellular milieu which were necessary for AAV assembly ([@bib7]). Helper-virus independent genotoxic or cytotoxic factors such as SV40 LTAg that transformed or altered the cell cycle have been shown to support AAV replication and assembly ([@bib40], [@bib51], [@bib29], [@bib50], [@bib37]), highlighting the AAV dependence on cellular components. Direct involvement of cellular proteins in AAV replication, e.g. ssDNA binding protein, replication protein (RPA), replication factor C (RFC) and proliferating cell nuclear antigen (PCNA), have been extensively studied and displayed as much replication activity as Adenoviral helper function ([@bib38]). Indirect function of cellular factors in AAV replication required their interactions with AAV proteins ([@bib24], [@bib9], [@bib21], [@bib41]). For example, the interaction of cellular proteins SP1, YY1, Topors or TATA-binding protein (TBP) with Rep protein resulted in the assemblage of a transcription imitation complex e.g. p5-Rep-SP1-p19, which led to the initiation of AAV DNA replication and expression ([@bib42], [@bib22]; [@bib18]; [@bib52]). Early studies have shown that AAV replication required only the AAV leading strand DNA synthesis and was thus independent of α, δ, ε DNA polymerases ([@bib38], [@bib55]), suggesting a potential requirement of novel cellular proteins for AAV replication.

A number of studies have shown that DNA binding proteins played a vital role in AAV life cycle; for example, at the early stage of AAV replication, DNA-binding proteins interacted with the AAV ITR sequence for unwinding AAV dsDNA, nicking ssDNA, facilitating ssDNA association with nuclei and ultimately enhancing viral DNA production and protein expression ([@bib56]). At the late stage of the AAV life cycle, DNA-binding proteins were required for viral DNA accumulation, translocation and the formation of viral DNA-protein complexes to facilitate virus assembly ([@bib56]). Virus-originated DNA binding proteins, e.g. helper Adenovirus E2A and HSV UL29, have been extensively studied showing inherent functions throughout the AAV life cycle; however, some studies have likewise showed that cellular proteins, e.g. total HeLa cell proteins and DNA helicase, could support helper virus-independent replication of AAV virus, indicating an alternative cellular mechanism(s) in the AAV life cycle ([@bib51], [@bib29], [@bib50], [@bib37]). A number of cellular DNA binding proteins, e.g. ssDNA binding protein, ANP32B, NCL, YB1 and NPM1, have been shown to play a role in the AAV life cycle ([@bib38], [@bib35]; [@bib39]; [@bib47]; [@bib10]).

The G-quadruplex DNA sequence (GQRS) is gaining increasing attention because it is highly represented in selected regions of the genome, e.g. telomeres and gene promoters. The G-quadruplex sequences have been recently identified within the genome of a number of viruses, e.g. HIV, HSV, EBV influenza, papillomavirus and cauliflower mosaic virus ([@bib44], [@bib1]; [@bib53]; [@bib33]; [@bib31]; [@bib17]). It is generally believed that the viral GQRS structure formed steric road blocks to DNA replication and transcription ([@bib17], [@bib23]). Destruction of G-quadruplex by GQRS ligands, e.g. BRACO-19, could effectively unblock GQRS inhibition of viral DNA replication of HIV and HSV viruses ([@bib17], [@bib43]). Furthermore, previous studies have shown that interaction of NPM1 with DNA GQRS could lead to the repression of cellular and viral DNA replication ([@bib48], [@bib49]). There has been so far no report on the presence or function of GQRS structure within the AAV genome.

A previous study has showed that NPM1 existed in close proximity to Cap or Rep proteins and most prevalently with AAV Cap. Agents that augmented AAV infection, such as helper adenovirus, herpesvirus or genotoxic agents were known to redistribute nucleolar proteins, e.g. NPM1 and NCL, away from the nucleolus, indicating potential NPM1 negative regulation on AAV replication ([@bib45], [@bib32], [@bib26], [@bib27]). Following up our previous proteomics study on the function of cellular proteins on AAV production ([@bib47]), this study focused on the DNA binding protein, Nucleophosmin (NPM1) that showed a clear association with AAV ([@bib39]; [@bib47]; [@bib10]; [@bib16]), on its function and cellular-viral interaction during AAV replication. Understanding these mechanism(s) may enable us to manipulate AAV biological processes and to improve AAV vectors as a gene delivery system.

2. Materials and methods {#s0010}
========================

2.1. Gene knockdown with shRNA {#s0015}
------------------------------

Small hairpin RNA (shRNA) for NPM1 knockdown were transfected with the presence of Lipofectamin 2000 (Life Technologies, Baltimore, MD, USA) into 293T cells according to the manufactureer\'s protocol. Control cells were transfected with empty capsids without a shRNA sequence. Transfection efficiency was evaluated by Western blotting.

2.2. shRNA interference and the establishment of gene knockdown cell lines {#s0020}
--------------------------------------------------------------------------

Five small hairpin RNA (shRNA) sequences were used for gene knockdown of NPM1 and were expressed from plasmid pLKO.1-puro (Sigma, USA) using a Lentiviral expression system. shRNA and lentiviral vector packaging plasmids were transfected into 293T cells using the CaCl~2~ transfection method. Control cells were transfected with empty capsids without a shRNA sequence (mock) or a scramble shRNA sequence targeting non-mammalian gene sequences (scramble).

2.3. AAV production {#s0025}
-------------------

Three AAV serotypes, i.e. AAV2, AAV5 and AAV8, were produced and investigated in this study. AAV particles were produced using the Calcium phosphate-BBS method and from 3 plasmids pHelper (Stratagene, USA), pAAV-RC encoding AAV Rep-Cap and pAAV-hrGFP (Stratagene, USA), as detailed in our previous study ([@bib47]). Vector producer cells were harvested and were subjected to 5 cycles of freeze thaw to release vector particles and the cellular debris was removed by centrifugation (2000 g). AAV vectors were purified by ultra-centrifugation at 4000 rpm for 3 h on a step gradient containing 15%, 25%, 40% and 60% iodixanol.

2.4. Sample preparation for transduction vector genome titration {#s0030}
----------------------------------------------------------------

AAV vectors produced from control, scramble or gene-knockdown cells were used to transduce Hela cells (ATCC, USA) overnight. Cytoplasmic DNA extraction was the same as vector DNA except without Proteinase K digestion of capsid proteins. Genomic DNA was extracted using a Wizard^@^DNA Genomic purification kit (Promega, USA) before being subjected to quantitation of the housekeeping gene Actin for sample normalisation and the determination of AAV transduction genome titres, using qPCR as described in our previous study ([@bib47]). Genome titre of AAV vectors was determined using real-time qPCR with AAV2 ITR primers: ITR-F 5'-GGA ACC CCT AGT GAT GGA GTT-3', ITR- R 5'-CGG CCT CAG TGA GCG A-3' and ITR-P 5'-CAC TCC CTC TCT GCG CGC TCG-3'and as detailed in our previous study ([@bib57]).

2.5. Immunochemistry {#s0035}
--------------------

SDS-polyacrylamide gel electrophoresis (10% total acrylamide) was used to resolve protein samples and followed by immunoblotting. Samples for immunoblotting were electrophoresed and electroblotted to Hybond ECL membranes (Amersham, UK). The following primary antibodies were used: mouse anti AAV2 Rep (Fitzgerald, USA) and AAV2 Cap (Abcam, UK), anti NPM1 (Abcam, UK) and anti GAPDH (Abcam, UK). The immunoblots were further incubated with goat anti-mouse, anti-rabbit or rabbit anti-goat horseradish peroxidase conjugates (Sigma, UK). The immuno-reactive proteins were detected using ECL reagents (Amersham, UK). The level of gene knockdown was evaluated using 10 μg total proteins from shRNA virus-transduced cells following the immunoblotting method as described above. AAV2 capsid proteins were quantified using an ELISA kit and following the manufacturer\'s protocol (Progene, USA) and presented as capsid/mL according to the manufacture\'s standard curve conversion.

Parental 293T cells and NPM1 knockdown cells, before and after transfection with AAV production plasmids, were fixed with 4% formaldehyde, permeabilised in PBS with 0.1% Triton X-100 (Sigma, USA) and blocked with immunofluorescence buffer before being labelled individually or in combination with the following antibodies: mouse anti NPM1 (Thermo, USA), rabbit anti-NPM1 (Bethyl USA), rabbit anti-AAV Cap (Progen, Germany) and mouse anti-AAV Rep (Fitzgerald, Germany). Antibody-labelled cells were then incubated with AlexaFluor-488 conjugated goat anti-rabbit or DyLight 633 conjugated goat anti-mouse antibodies (ThermoFisher, USA). Nuclei were labelled with Dapi (Sigma, USA). The labelled cells were visualised with a Leica SPX upright laser scanning confocal microscope and analysed using Leica Application Suite X (LASX) software.

Protein-protein interaction assay was performed using G-coupled agarose beads to immunoprecipate anti-NPM1 or mouse anti-Cap antibody interacted proteins in cell lysates before being subjected to immunoblot analysis.

Flow cytometry was performed using a BD FACSCanto II™ machine (BD Biosciences, Oxford, UK). Cells were gated based on forward angle light scatter (FSC) and side angle light scatter (SSC) characteristics and further analysed using BD FACSDiva™ software version 6.1.1 (BD Biosciences).

2.6. G-Quadraplex (GQRS) DNA binding assay {#s0040}
------------------------------------------

Three biotin-labelled GQRS DNA oligonucleotides (Invitrogene, USA), that is ITRA 5'-TCG GGC GTC GGG CGA CCT TTG GTC GCC TTT TT-Biotin-3', and ITRB 5'-TGA GGG AGT GGC CAA CTC CAC ACT AGG GGT TCC TTT TT-Biotin-3', targeting different regions of AAV2 *ITR* were synthesised and a *c-myc* specific biotin-oligonucleotide MYC 5'-TGA GGG TGG GGA GGG TGG GGA AGG TTT TT-Biotin-3' and a non-GQRS biotin-oligonucleotide NGQRS 5'-GCA GCC ATC GCG TCA GAC GCG GAA GCT TCG ATC AAC TAC TTTT-Biotin-3' were synthesised as a positive control and a negative control, respectively. For each corresponding sequence, a non-biotinylated oligonucleotide was also synthesised for a competition assay. The GQRS DNAs were denatured at 65 °C for 10 min, and cooled to room temperature to allow the formation of GQRS structures. Cell lysates from 293T cells or NPM1 knockdown cells before or after transfection and AAV production were incubated in the presence of GQRS DNA at 4 °C overnight before streptavidin beads were added. The GQRS DNA-protein-bead complex was recovered using a magnet, washed and denatured in Laemmli buffer (SIGMA, USA) at 98 °C for 5 min and finally subjected to immunoblot analysis. Competition assay was performed by adding a dilution series of non-biotin labelled *c-myc* GQRS DNA to the biotin-labelled *ITR* GQRS DNA before it being subjected to DNA-protein interaction.

2.7. Statistical analysis {#s0045}
-------------------------

Statistical analysis was carried out using GraphPad Prism 5 (GraphPad Software Inc., CA, USA). Data was tested for normality using the Kolmogorov-Smirnov test then analysed using a one-way ANOVA followed by Bonferroni\'s Multiple Comparison Test or a Kruskall Wallis test followed by Dunn\'s Multiple Comparison Test. A p-value of \< 0.05 was considered statistically significant.

3. Results {#s0050}
==========

3.1. Establishment of NPM1 knockdown cells {#s0055}
------------------------------------------

Our previous proteomics and mass spectrometry study has shown that the NPM1 protein was detected in purified AAV vectors ([@bib47]), suggesting a possible role of NPM1 in AAV assembly. [Fig. 1](#f0005){ref-type="fig"}**A** analysed NPM1 expression dynamics during a complete cycle of AAV2 and AAV8 production, showing that the expression of NPM1 decreases overtime 24 h after the transfection. In correlation, the expression of AAV Rep and Cap (VP1, VP2 and VP3) became detectable at a similar time point when NPM1 expression starts to decline ([Fig. 1](#f0005){ref-type="fig"}**B**), indicating a potential negative regulation of AAV proteins on NPM1 expression. In order to study the function of NPM1 protein in AAV replication and assembly, we used a Lentiviral vector delivery system, as detailed before ([@bib47]), to establish NPM1 knockdown cells with five NPM1 specific shRNA sequences, i.e. shRNA_M1 to M5 ([Fig. 1](#f0005){ref-type="fig"}**C**). Introducing a shRNA sequence to parental 293T cells led to the significant down-regulation of NPM1 expression ([Fig. 1](#f0005){ref-type="fig"}**C)** compared to NPM1 expression in two control cells that were either with scramble shRNA targeting non-mammalian genes (scramble) or without any shRNA sequences (293T); in particular, shRNA_M1 and M4 sequences (circled, [Fig. 1](#f0005){ref-type="fig"}**C**) led to the most gene knockdown and, the reduction of NPM1 expression ([Fig. 1](#f0005){ref-type="fig"}**D**) sustained for over 90 days after culture in puromycin selection medium, demonstrating the robustness of shRNA gene regulation. Analysis of LV_shRNA integration showed that an average of 1 copy/ cell of NPM1 shRNA sequence integration led to the significant down-regulation of NPM1 expression in knockdown cells.Fig. 1Immunoblotting analysis of NPM1 and AAV protein expression in parental 293T cells after transient transfection of AAV packaging and helper plasmids, showing (**A**) overtime decrease in NPM1 expression in AAV 2 and AAV8 producer cells; (**B**) detection of AAV capsid (VP1, VP2 and VP3) and Rep proteins from 24 h after transfection; (**C**) NPM1 knockdown in LV-NPM1-shRNA transduced 293T cells carrying shRNA M1 to M5 sequences targeting *NPM1*; (**D**) sustained down-regulation of NPM1 in single cell clones and in culture for up to 90 days. Controls: 293T cell lysate without the transfection of any plasmids (293T), 293T cells with the transfection of pcDNA3.1 plasmids (Mock); 293T cells with a shRNA sequence targeting non-mammalian genes (Scramble) and without any shRNA sequences (293T) were used as gene knockdown controls. Housekeeping gene GAPDH was further used as a loading control.Fig. 1

3.2. Influence of NPM1 knockdown on AAV titre {#s0060}
---------------------------------------------

The effect of NPM1 gene knockdown on AAV production was tested for AAV2 and AAV8 carrying a reporter gene GFP. Down-regulation of NPM1 in producer cells led to up to 35 fold increase in AAV titres of AAV2 ([Fig. 2](#f0010){ref-type="fig"}**A,** [Table 1](#t0005){ref-type="table"}) and AAV8 ([Fig. 2](#f0010){ref-type="fig"}**B,** [Table 2](#t0010){ref-type="table"}) compared to control scramble cells. It is noteworthy that [Fig. 2](#f0010){ref-type="fig"}**A and B** show collective data on vectors produced from bulk cells and single cell clones. Each data point is a mean relative titre of triplicate lots of vectors produced from 3 independent experiments of a given cell line at one time point, as detailed previously ([@bib47]). The reason for us to present collective data on the same figure from different cell lines/clones at different time points is to show not only the relative titres but also the optimal range of production time for NPM1 knockdown cells. On average, NPM1 knockdown cells and parental 293T cells produced AAV2 and AAV8 vectors at around \~ 10^3^ and 10^2^ VG/cell, respectively.Fig. 2Relative genome titres of AAV vectors produced from NPM1 gene knockdown cells compared to that from control scramble cells, showing up to 35 fold and 30 fold increases in **(A**) AAV2 and (**B**) AAV8 vector genome titres (VG/mL), respectively, compared to scramble cells and throughout 90 days in culture; (**C**) NPM1 expression in individual AAV producer cell lines at the last production time points. Different sympols, e.g. square or circle etc, represent independently established NPM1 knockdown cell lines. (**D**) *in vitro* transduction on HelaS3 cells (left panel, labelled in green, GFP) and *in vivo* transduction in Balb C mice (right panel, in blue, luciferase) showing comparable transduction efficiency when using AAV2 vectors produced from control scramble cells (Scr/AAV2luc) or from NPM1 knockdown cells (NPM/AAV2luc). Scale bars are 30 µm.Fig. 2Table 1AAV2 vector genome titres.Table 1**DaysAAV2Titre (VG/10**^**8**^**cells)Ratio N/SBatch 1**24Scramble5.24 ± 0.15 × 10^9^NPM1.11 ± 0.17 × 10^10^2.12**Batch 2**24Scramble5.24 ± 0.15 × 10^9^NPM1.24 ± 0.24 × 10^10^2.37**Batch 3**26Scramble1.63 ± 0.25 × 10^1^NPM4.93 ± 0.31 × 10^11^3.29**Batch 4**32Scramble2.60 ± 0.06 × 10^10^NPM1.24 ± 0.14 × 10^11^4.77**Batch 5**30Scramble2.60 ± 0.06 × 10^10^NPM1.31 ± 0.17 × 10^11^5.04**Batch 6**35Scramble4.96 ± 2.50 × 10^10^NPM2.64 ± 0.41 × 10^11^5.32**Batch 7**39Scramble5.50 ± 1.70 × 10^10^NPM7.52 ± 1.12 × 10^11^13.73**Batch 8**42Scramble8.00 ± 0.48 × 10^9^NPM1.15 ± 0.36 × 10^11^14.38**Batch 9**49Scramble2.73 ± 0.74 × 10^9^NPM7.88 ± 0.87 × 10^10^28.86**Batch 10**69Scramble2.73 ± 0.74 × 10^9^NPM8.64 ± 0.27 × 10^10^31.65**Batch 11**90Scramble1.86 ± 0.67 × 10^9^NPM6.36 ± 0.74 × 10^10^34.1Table 2AAV8 Vector Genome Titres.Table 2**DaysAAV8Titre (VG/10**^**8**^**cells)Ratio N/SBatch 1**15Scramble2.54 ± 0.34 × 10^7^NPM1.34 ± 0.06 × 10^8^5.26**Batch 2**21Scramble2.05 ± 0.19 ×10^7^NPM1.37 ± 0.14 × 10^8^6.68**Batch 3**30Scramble8.28 ± 0.83 × 10^7^NPM8.80 ± 2.11 × 10^8^10.63**Batch 4**38Scramble8.28 ± 0.83 ×10^7^NPM2.42 ± 0.24 × 10^9^29.28**Batch 5**72Scramble8.28 ± 0.83 × 10^7^NPM1.55 ± 0.85 × 10^9^18.67**Batch 6**90Scramble2.54 ± 0.34 × 10^7^NPM1.60 ± 0.24 × 10^8^6.3

Due to the fact that NPM1 knockdown cells cannot be established as single cell clones, all results presented were based on bulk population of NPM1 knockdown cells. Although the NPM1 expression level ([Fig. 2](#f0010){ref-type="fig"}**C**) and the average integration copies of LV_NPM1 shRNA (\~2/cell) were comparable among different batches of cell lines, we observed a greater batch-to-batch variation in terms of AAV8 production compared to that of AAV2 production, indicating a serotype specific response to NPM1 knockdown.

Using an equal genome copy number of purified AAV2/GFP vectors to transduce HelaS1 cells in vitro ([Fig. 2](#f0010){ref-type="fig"}**D,** left panel) or purified AAV2/Luciferase vectors to transduce Balb/C mice intramuscularly ([Fig. 2](#f0010){ref-type="fig"}**D,** right panel), we observed a comparable or slight increased infectivity of the AAV2 produced from NPM1 knockdown cells compared to that produced from control scramble cells, demonstrating the robustness of NPM1 knockdown cells in producing infectious and functional AAV.

Using a quantitative ELISA with an antibody specific for assembled AAV capsid particles, we detected two fold higher amounts of AAV capsid particles in control scramble cells than that in NPM1 knockdown cells, at 1.11 ± 0.15 × 10^14^ and 5.51 ± 0.26 × 10^13^ particles/10^8^cells, respectively ([Table 3](#t0015){ref-type="table"}); whereas, the number of complete AAV particles carrying AAV genome ( i.e. AAV genome titre) were up to 35 fold higher in NPM1 knockdown cells than that in scramble cells, indicating a greater production of empty particles without vector genome in scramble cells compared to NPM1 cells.Table 3Production of AAV2 capsid particles.Table 3**ELISAParticles% of Total particlesRatioper 10⁸ cellsin whole cellsS/NWhole cells**Scramble1.11 ± 0.15 × 10^14^100%2.01NPM5.51 ± 0.26 × 10^13^100%**Cytoplasm**Scramble7.49 ± 0.80 × 10^12^6.77%1.2NPM9.02 ± 0.82 × 10^12^16.35%**Nuclei**Scramble1.03 ± 0.01 × 10^14^93.23%2.23NPM4.61 ± 0.89 × 10^13^83.64%**Vectors**Scramble4.36 ± 0.77 × 10^13^39.20%1.36NPM2.97 ± 0.74 × 10^13^53.38%

3.3. Influence of NPM1 knockdown on Plasmid DNA transfection {#s0065}
------------------------------------------------------------

To study whether NPM1 knockdown influenced the first step of AAV production, i.e. the entry of plasmid DNA into cells, plasmid DNA inside transfected cells were analysed using qPCR targeting AAV2 *rep* sequence ([Table 4](#t0020){ref-type="table"}). The reason to choose *rep* instead of *ITR* sequence as an indication of DNA transfection efficacy is because *rep* DNA plasmids, by design, do not have DNA replication capacity in the transfected cells. [Table 4](#t0020){ref-type="table"} showed that, 8.10% and 9.54% of total input of 6.8× ×10^13^ copies of *rep* plasmids DNA, i.e. 5.51 ± 0.43 × 10^12^ and 6.49 ± 0.19 × 10^12^ copies, were detected in scramble and NPM1 knockdown cells respectively, representing a \~ 8% and \~ 5 × 10^4^ copies/cell transfection efficiency when using the calcium transfection protocol. The comparable transfection efficiency in scramble and NPM1 knockdown cells indicated that NPM1 knockdown did not significantly influence the transfection efficiency thus the transfection process might not contribute to the increased AAV titre observed in NPM1 knockdown cells. However, NPM1 knockdown influenced the distribution of plasmid DNA, with over 2 fold higher amount of plasmid DNA detected in NPM1 knockdown cells compared to control scramble cells ([Table 4](#t0020){ref-type="table"}).Table 4Influence of NPM1 knockdown on plasmid DNA transfection.Table 4**qPCRAssessmentLocationSamplesDNA Copies/10**^**8**^**cells% InputRatioTargetN/S**input6.8x x10^13^**100%DNA TransfectionWhole cells**Scramble5.51±0.43 x10^12^**8.10%*****Rep***NPM6.49±0.19 x10^12^**9.54%1.18Cytoplasm**Scramble2.73±0.57 x10^12^NPM1.57±0.76 x10^12^**0.57Nuclei**Scramble4.49±0.38 x10^11^NPM1.01±0.25 x10^12^**2.25**

3.4. Influence of NPM1 knockdown on viral DNA production {#s0070}
--------------------------------------------------------

To investigate whether NPM1 knockdown influences viral DNA replication, DNA extracted from producer cells 72 h after transfection was quantified by qPCR targeting *ITR* sequence. Our results showed that 91.7% and 195% of input *ITR* plasmids at 2.6 × 10^13^ copies/10^8^cells were detected, that is a total of 2.37 ± 0.73 × 10^13^ and 5.08 ± 0.38 × 10^13^ copies of *ITR* DNA detected in 10^8^ scramble and NPM1 knockdown cells, respectively. Taking into account the fact that the transfection efficiency was \~ 8% using the adopted transfection method ([Table 4](#t0020){ref-type="table"}), the majority of the detected *ITR* DNA was from AAV DNA replication. In addition, the amount of *ITR* DNA detected in NPM1 knockdown cells was 2.14 fold higher than that in control scramble cells, indicating that NPM1 knockdown significantly enhanced viral DNA replication, resulting in the significant increase in AAV titres.

3.5. NPM1 Interaction with AAV DNA {#s0075}
----------------------------------

To understand how NPM1 knockdown enhanced AAV DNA replication, the interaction of NPM1 proteins with AAV DNA was systematically investigated. It has been previously reported ([@bib20], [@bib15]) that NPM1 protein showed high affinity interaction with single strand and complex DNA; in particular, the interaction of NPM1 with a G-quadruplex (GQRS) sequence from the *c-myc* promoter plays an important role in the onset of acute myeloid leukaemia (AML) disease ([@bib48]). The interaction of a G-quadruplex structure in the U3 region of HIV-1 genome with transcription factor Sp1 led to HIV-1 reactivation and high-level virus expression. Using software for G-quadruplex sequence prediction and analysis (www.bioinformatics.ramapo.edu/qgrs/analyse.php), we identified a total of 18 GQRS structures within the AAV2/*ITR* region. Two non-overlapping AAV GQRS sequences, named *ITRA* and *ITRB* in this study, were selected and were biotin-labelled to study their interaction with endogenous NPM1 proteins in parental 293T cells. [Fig. 3](#f0015){ref-type="fig"}**A** showed that NPM1 proteins were pulled down by a control *c-myc* promoter GQRS ([Fig. 3](#f0015){ref-type="fig"}**A**, lane 1) and *ITR* predicted GQRS sequences *ITRA* ([Fig. 3](#f0015){ref-type="fig"}**A**, lane 2) when using the DNA binding assay as described in Methods and Materials. There was a trace amount of NPM1 detected in NPM1 knockdown cells when using *c-myc* or AAV *ITRA* GQRS ([Fig. 3](#f0015){ref-type="fig"}**A**, lane 4 and 5), reflecting the reduced NPM1 expression in NPM1 knockdown cells. No NPM1 proteins were detected in control 293T cells when using a random non-GQRS DNA oligonucleotide (NGQRS) ([Fig. 3](#f0015){ref-type="fig"}**A**, lane 6) to perform a DNA binding assay.Fig. 3Protein-DNA binding assays showing **(A)** NPM1 interaction with GQRS structure within *c-myc* (myc, 1st lane) and AAV *ITR* sequences (ITRA, 2nd lane) in 293T cells after transfection with AAV packaging plasmids and a trace NPM1 interaction with *c-myc* (myc, 4th lane) and *ITR* (ITRA, 5th lane) GQRS in NPM1 knockdown cells after AAV plasmid transfection; a non-GQRS DNA oligonucleotide (NGQRS) was included as nonspecific DNA binding control (NGQRS, 6th lane); **(B)** Competition for AAV\_*ITR* binding to NPM1 proteins using an increased amount of *c-myc* GQRS (top and middle panels): a progressively diminishing of *ITR_A* (top panel) or *ITR_B* GQRS (middle panel) binding to NPM1 proteins; a non-GQRS DNA oligonucleotide (NGQRS, bottom panel) was also used as assay control, showing that non-GQRS DNA oligonucleotides (NGQRS) cannot compete out the AAV *ITR_A* GQRS binding to NPM1 proteins (bottom panel) and that AAV ITR binding to NPM1 proteins is GQRS specific; **(C)** NPM1 expression in 293T and NPM1 knockdown cells before DNA binding assays. A non-GQRS DNA oligonucleotide (NGQRS) was included as nonspecific DNA binding control and Housekeeping gene GAPDH was used as a loading control.Fig. 3

To evaluate the specificity of NPM1 binding to AAV GQRS, we carried out a competition assay with the same *c-myc* promoter GQRS as previously reported ([@bib48]). [Fig. 3](#f0015){ref-type="fig"}**B** shows that NPM1 binding to biotin-labelled *ITR*/GQRS can be competed out and a progressively reduced amount of NPM1 were detected when an increased amount of non-biotin-labelled *c-myc* GQRS was added to 500 μg or 200 μg of total 293T cell lysate proteins, demonstrating a GQRS specific binding of AAV *ITR* sequences to NPM1 proteins. The expression of NPM1 in parental 293T and NPM1 knockdown cells was confirmed before performing GQRS-binding assays ([Fig. 3](#f0015){ref-type="fig"}**C**). Our study showed for the first time the presence of GQRS in AAV *ITR*, the interaction of NPM1 protein with the predicted AAV GQRS sequences *ITRA* and *ITRB,* and alongside the confirmation of NPM1 interaction with the same *c-myc* promoter GQRS as previously reported ([@bib48]).

3.6. Influence of NPM1 knockdown on AAV viral protein expression and localisation {#s0080}
---------------------------------------------------------------------------------

There was no significant difference between NPM1 knockdown (N) and control scramble (S) cells in terms of the expression and the localisation of AAV Rep ([Fig. 4](#f0020){ref-type="fig"}**A)** and Cap ([Fig. 4](#f0020){ref-type="fig"}**B)** proteins; moreover, both Rep and Cap proteins were predominantly associated with the insoluble fraction of cellular/nuclei membranes ([Fig. 4](#f0020){ref-type="fig"}). No Rep or Cap proteins were detected in the mock-transfected control 293T cells with pcDNA3.1 plasmids without AAV sequences (data not shown).Fig. 4Immunoblotting analysis of AAV protein showing a comparable **(A)***rep* and **(B)***cap* expression between control scramble cells and NPM1 knockdown cells and comparable distribution of Rep and Cap proteins in cytoplasm, nuclear and insoluble membrane fractions of control scramble (S) and NPM1 knockdown (N) producer cells.Fig. 4

[Fig. 5](#f0025){ref-type="fig"} showed that under fluorescence microscopy, AAV Rep proteins predominantly located in the nuclei ([Fig. 5](#f0025){ref-type="fig"}, left panels, labelled in red) and Cap proteins predominantly in cytoplasm ([Fig. 5](#f0025){ref-type="fig"}, right panels, labelled in red). In addition, there is no significant difference between NPM1 knockdown ([Fig. 5](#f0025){ref-type="fig"}**,** top panels) and control 293T cells ([Fig. 5](#f0025){ref-type="fig"}, middle panels) in the localisation of AAV Rep ([Fig. 5](#f0025){ref-type="fig"}, left panel) and Cap ([Fig. 5](#f0025){ref-type="fig"}, right panel**)** proteins. The bottom panel of [Fig. 5](#f0025){ref-type="fig"} showed the nuclear localisation of endogenous NPM1 ([Fig. 5](#f0025){ref-type="fig"}, labelled in green) and NPM1 co-localisation with AAV proteins ([Fig. 5](#f0025){ref-type="fig"}, labelled in red) in the 293T cells. No NPM1 proteins were detected in NPM1 knockdown cells (data not shown). [Fig. 6](#f0030){ref-type="fig"} showed that using an AAV capsid particle-specific antibody, the assembled AAV capsid were predominantly located in cytoplasm in NPM1 knockdown cells ([Fig. 6](#f0030){ref-type="fig"}, left panels, labelled in red), such a cytoplasmic localisation of the capsid particles was less evident in 293T cells ([Fig. 6](#f0030){ref-type="fig"}**,** right panels).Fig. 5Fluorescence microscopy of NPM1 and AAV Rep and Cap proteins; showing nuclear localisation of AAV Rep (labelled in red, left panels) and NPM1 proteins (in green, bottom panels) and cytoplasm localisation of AAV Cap protein (in red, right panels) in NPM1 knockdown cells (top panels) and parental 293T cells (middle and bottom panels) after transient transfection of AAV packaging and helper plasmids. Nuclei were labelled with Dapi in blue. Scale bars are 50 µm.Fig. 5Fig. 6Confocal microscopy of assembled AAV2 particles (labelled in red): showing cytoplasm localisation of AAV particles in NPM1 knockdown cells (labelled in red, left panels) compared to nuclear localisation of AAV particles in control 293T cells (labelled in red, right panels). Nuclei were labelled with Dapi in blue. Scale bars are 200 µm for top panel and 15 µm for bottom panel.Fig. 6

4. Discussion {#s0085}
=============

Our results showed for the first time that down-regulation of nucleolar protein Nucleophosmin (NPM1) resulted in up to 35 fold increase in AAV2 and AAV8 vector production. AAV production could be divided into the following stages: stage (1) entry of plasmid DNA into the producer cell nuclei, (2) AAV Rep and Cap protein expression, (3) AAV empty capsid assembly in nuclei ([@bib58]), (4) AAV vector DNA amplification, (5) vector DNA-capsid packaging into fully assembled particles, (6) maturation of DNA-packaged particles (full particles) and finally (7) the matured full particles released from nuclei into cytoplasm ([@bib28]). In this study, NPM1 knockdown showed direct influence on 3 stages of AAV production process, that is, slight increase in AAV plasmid DNA entering nuclei (stage 1), significant increase in AAV DNA amplification (stage 4) and increase in mature AAV particles being released from nuclei to cytoplasm (stage 7), and ultimately led to significant increase in AAV vector production. Our results demonstrated an intrinsic NPM1 negative regulation on AAV replication and production.

The observed influence of NPM1 knockdown on AAV DNA amplification might largely attribute to the NPM1 DNA binding property. Nucleophosmin is a nucleolar protein with many functions including genome stability, DNA duplication and transcriptional regulation ([@bib12], [@bib4]). NPM1 showed high binding affinity to single-stranded nuclei acids and a negative regulation on DNA replication via DNA G-Quadruplex sequence (GQRS) ([@bib15], [@bib11]). For example, binding of NPM1 to the DNA G-Quadruplex sequence (GQRS) within the c-*myc* promoter caused a marked down-regulation of c-*my*c oncogene ([@bib15], [@bib43]). Furthermore, previous studies have also shown that interaction of NPM1 with DNA GQRS could lead to the repression of cellular and viral DNA replication ([@bib48], [@bib49]).

Destruction of G-quadruplex by GQRS ligands, e.g. BRACO-19, could effectively unblock GQRS inhibition of viral DNA replication of HIV and HSV viruses ([@bib17]). In addition to the GQRS functions due to its unique structure, the interaction of DNA GQRS with cellular proteins, e.g. Nucleolin and NPM1, could also lead to the repression of cellular and viral DNA replication ([@bib48], [@bib49]). Federici et al. showed that NPM1 preferentially bound to the GQRS region and induced the formation of GQRS structures in cellular DNA, e.g. SOD2 gene promoter. Studies have also shown that direct NPM1 interaction with adenoviral DNA interfered with adenoviral DNA replication ([@bib19], [@bib46]). Mutations of MPN1 that prevented NPM1 interaction with GQRS structure led to oncogene expression and pathogenesis of acute myeloid leukaemia ([@bib2]), further demonstrating a GQRS dependent mechanism of NPM1 in gene regulation.

There has been so far no report on the presence or function of the GQRS structure within the AAV genome. Our results showed for the first time that NPM1 interaction with AAV ITR was GQRS specific as NPM1 binding to the two GQRS within AAV *ITR* could be competed out by *c-myc*/GQRS. It is likely that the observed increase in AAV vector DNA production in NPM1 knockdown cells might be due to (1) that NPM1 knockdown removed the NPM1 induction of GQRS structure formation and thus reduced the road blocks to AAV vector DNA replication, and (2) NPM1 knockdown removed NPM1 interaction with AAV DNA and thus reduced NPM1 negative regulation of AAV DNA replication. This ultimately led to the significant increase in AAV DNA replication and AAV production in NPM1 knockdown cells, which was consistent with the proposed function of GQRS and NPM1-GQRS interaction in DNA regulation ([@bib31], [@bib17], [@bib23]).

The well-established NPM1 function as a chaperone protein ([@bib12], [@bib4]) might contribute to the observed influence of NPM1 knockdown on the matured and packaged AAV particles being released from nuclei into cytoplasm. NPM1 regulation of virus life cycle has been so far considered predominantly as a result of direct NPM1 and viral protein-protein interaction ([@bib3], [@bib19], [@bib54], [@bib30], [@bib14]). Endogenous NPM1 has been reported to create a barrier at the early stage of AAV infection for subcellular AAV trafficking and for AAV capsid mobilisation from nucleolus to nucleoplasm, highlighting the chaperone property of NPM1 proteins ([@bib30]). [@bib58] has shown that AAV Cap proteins accumulated in the nucleolus in the absence of Rep protein or AAV DNA, suggesting that AAV empty capsid assembly occurred in the nucleolus. [@bib46] has demonstrated that NPM1 knockdown significantly increased the accumulation of Adenovirus capsids in nuclei and the packaging of viral DNA with Adenovirus core proteins and ultimately influenced the maturation of Adenovirus particles. Although there have been no direct reports of NPM1 function on AAV packaging and maturation, our results showed that NPM1 knockdown led to increased localisation of packaged AAV particles in cytoplasm in NPM1 knockdown cells, supporting the proposed mechanism by [@bib46] of NPM1 knockdown in virus assembly, maturation and trafficking.

The expression of AAV Rep and Cap proteins and the localisation of un-assembled Cap proteins were not significantly affected by NPM1 knockdown, indicating that the observed NPM1 barrier for subcellular trafficking of AAV proteins during AAV infection was not occurring during AAV production. This might be because the presence of Adenoviral helper function in the AAV production system had redistributed NPM1 away from nucleolus, as reported previously ([@bib26], [@bib27]). NPM1 expression has been previously reported to decrease in cells undergoing apoptosis and NPM1 was considered as an anti-apoptotic protein ([@bib13]). Such progressive decrease in NPM1 expression was also detected during AAV production in this study, reflecting the induced-apoptosis by the expression of AAV and adenoviral helper virus.

5. Conclusion {#s0090}
=============

In summary, this study systematically investigated NPM1 function on AAV vector production, revealing for the first time the presence of GQRS in the AAV genome, the synergistic NPM1-GQRS function in AAV production and the significant enhancement of NPM1gene knockdown on AAV vector production. Our earlier study has likewise shown a similar enhanced AAV vector production by another DNA binding protein, Y-box protein 1 (YB1) ([@bib47]), revealing that NPM1 and YB1, which are both DNA binding proteins, might utilise different mechanisms in influencing AAV production. For example, knockdown YB1 removed its competition with Adenovirus E2A and AAV capsid proteins for binding to a specific GGGG(TT) motif in the ITR sequence and thus increased Adenovirus-helped AAV DNA production and packaging ([@bib47]). NPM1 knockdown removed NPM1-induced formation of GQRS structure and thus reduced the road blocks to AAV vector DNA replication. Although double knockdown of NPM1 and YB1 did not have an add on effect on AAV production (data not shown), our studies highlighted an imperative function of these DNA binding proteins in the AAV life cycle. Understanding the role of cellular proteins in the AAV life cycle would greatly facilitate future production of high titre AAV vectors and may reduce the production of defective empty particles and, ultimately improve the quality and safety of AAV vectors for clinical use.
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